市場調査レポート

商品コード

1447818

mRNA治療の世界市場規模、シェア、成長分析、タイプ別、用途別-産業予測、2024～2031年

Global mRNA Therapeutics Market Size, Share, Growth Analysis, By Type(Prophylactic Vaccines, Therapeutic Vaccines), By Application(Rare Genetic Diseases, Oncology) - Industry Forecast 2024-2031

出版日: 2024年02月27日 | 発行: SkyQuest

| ページ情報: 英文 157 Pages | 納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 832,842円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 974,268円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,115,694円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
目次

概要

サンプル依頼リストに入れる

mRNA治療の世界市場規模は、2022年に408億米ドルと評価され、予測期間中（2024～2031年）のCAGRは2%で、2023年の416億2,000万米ドルから2031年には487億6,000万米ドルに成長する展望です。

mRNAベースの治療は、慢性疾患を効果的に治療する有望なソリューションとして最近大きな注目を集めており、市場の着実かつ確実な成長につながっています。最近では、mRNAワクチンがDNAワクチンよりも生産と流通における優位性から好まれるようになり、より安全な代替手段を提供しています。これらのワクチンや治療はヒト臨床試験に成功しており、これらの製品に対する需要をさらに押し上げています。ModernaやPfizer-BioNTechのような企業は、特にCOVID-19パンデミックの際に、この市場で大きな役割を果たしました。mRNA治療はがん臨床試験でも盛んに使用されており、2021年にはがん患者を対象としたmRNAワクチンの臨床試験が相当数のボランティアを集め、がん患者を対象としたCOVID-19の臨床試験を除いて参加者数第2位となりました。それ以来、この業界は目覚ましい成長を遂げています。世界中でSARS-CoV-2ウイルスの新型が出現したため、効果的なワクチンの必要性が強調され、医療関係者はmRNAワクチンに注目するようになりました。COVID-19パンデミックはmRNAベースの製品の利用を加速させ、市場拡大をさらに促進しました。メッセンジャーRNAは、翻訳や安定性を向上させる技術的進歩や送達技術のおかげで、強力な治療ツールとして台頭してきました。製薬業界は、mRNAワクチンによる市場拡大の可能性を認識しており、市場の有望な成長展望を示しています。その好例が、2020年3月にmRNA-1273（NIAID）を生み出したModerna Inc.と国立アレルギー感染症研究所との共同研究です。このワクチンは症候性COVID-19の予防に94.1％の有効率を示し、米国FDAから迅速承認を受け、2020年12月に緊急使用認可を受けた。さらに、急速に拡大するmRNA治療のセグメントは、個別化医療に革命をもたらし、従来の医療基準を一変させ、mRNAベースの製品に対する需要を当面増大させることになると考えられます。

技術分析
価格分析
サプライチェーン分析
バリューチェーン分析
市場のエコシステム
IP分析
貿易分析
スタートアップ分析
原材料の分析
イノベーションマトリクス
パイプライン製品の分析
マクロ経済指標
主要投資の分析
主要成功要因
競合の程度

市場力学と展望

市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
規制情勢
ポーターの分析
将来の混乱についての特別な考察

mRNA治療の世界市場：タイプ別

市場概要
予防ワクチン
治療用ワクチン
治療

mRNA治療の世界市場：用途別

市場概要
希少遺伝病
腫瘍学
呼吸器疾患
感染症
その他

mRNA治療の世界市場規模：地域別

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他の欧州地域
アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋
ラテンアメリカ
- ブラジル
- その他のラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2021年）
主要市場企業が採用した戦略
主要成功戦略
市場における最近の活動
主要企業の市場シェア（2021年）

主要企業プロファイル

CureVac AG（ドイツ）
Roche Holding AG（スイス）
Pfizer Inc.（米国）
GlaxoSmithKline plc（英国）
Moderna, Inc.（米国）
Sanofi SA（フランス）
BioNTech SE（ドイツ）
Dynavax Technologies Corporation（米国）
Arcturus Therapeutics Holdings Inc.（米国）
AstraZeneca plc（英国）
Regeneron Pharmaceuticals, Inc.（米国）
Alnylam Pharmaceuticals, Inc.（米国）
Gilead Sciences, Inc.（米国）
Mylan N.V.（米国）
Novartis AG（スイス）
Modulus Therapeutics, Inc.（米国）
Catalent, Inc.（米国）
Translate Bio, Inc.（米国）
Ionis Pharmaceuticals, Inc.（米国）
Vertex Pharmaceuticals Incorporated（米国）

Product Code: SQMIG35A2547

Global MRNA Therapeutics Market size was valued at USD 40.80 Billion in 2022 and is poised to grow from USD 41.62 Billion in 2023 to USD 48.76 Billion by 2031, at a CAGR of 2% during the forecast period (2024-2031).

mRNA-based therapeutics have recently gained significant attention as a promising solution for effectively treating chronic conditions, leading to the steady and assured growth of the market. In recent times, mRNA vaccines have become preferred over DNA vaccines due to their advantages in production and distribution, offering a safer alternative. These vaccines and therapeutics have successfully undergone human clinical trials, further boosting demand for these products. Companies like Moderna and Pfizer-BioNTech have played a major role in the market, particularly during the COVID-19 pandemic. Their vaccines developed in response to the global health crisis significantly fueled market growth. mRNA therapeutics are also prominently used in oncology clinical trials, with mRNA vaccine trials for cancer patients in 2021 attracting a substantial number of volunteers, ranking second highest in participation, excluding COVID-19 trials in cancer patients. The industry has witnessed remarkable growth since then. The emergence of new variants of the SARS-CoV-2 virus worldwide has emphasized the need for effective vaccines, prompting medical professionals to turn to mRNA vaccines. The COVID-19 pandemic accelerated the utilization of mRNA-based products, further driving market expansion. Messenger RNA has emerged as a powerful therapeutic tool, thanks to technological advancements that improve translation and stability, as well as delivery techniques. The pharmaceutical industry recognizes the potential for expansion through mRNA vaccines, indicating promising growth prospects for the market. mRNA vaccines represent the next stage in vaccine development, ushering in a new era in immunization. An excellent example of this is the collaboration between Moderna Inc. and the National Institute of Allergy and Infectious Diseases, which resulted in the creation of mRNA-1273 (NIAID) in March 2020. This vaccine demonstrated a 94.1% efficacy rate in preventing symptomatic COVID-19, receiving expedited approval from the US FDA and emergency use authorization in December 2020. Furthermore, the rapidly expanding field of mRNA therapeutics is set to revolutionize personalized medicine, transforming traditional healthcare standards and increasing the demand for mRNA-based products in the foreseeable future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global MRNA Therapeutics and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analysed to get the final quantitative and qualitative data.

Global MRNA Therapeutics Market Segmental Analysis

The global mRNA therapeutics market is segmented on the basis of type, application, region. By type, the market is segmented into prophylactic vaccines, therapeutic vaccines, therapeutic drugs. By application, the market is segmented into rare genetic diseases, oncology, respiratory diseases, infectious diseases, others. By end-use, the market is segmented into hospitals & clinics, research organizations, others. By region, the market is segmented into North America, Europe, Latin America, Asia- Pacific, Middle East and Africa.

Drivers of the Global MRNA Therapeutics Market

The COVID-19 pandemic accelerated the development of mRNA vaccines, highlighting mRNA technology's effectiveness in fighting infectious diseases.

Growing investments from public and private sectors, such as government agencies and venture capital firms, are fuelling research and development (R&D) activities in mRNA therapies.

An increase in clinical trials for a range of illnesses, including cancer, rare genetic disorders, and infectious diseases, is driving the market's growth.

Restraints in the Global MRNA Therapeutics Market

The global market for mRNA therapeutics encountered several challenges, particularly in the production and distribution processes. Scaling up mRNA production capacity while maintaining a stable supply chain was notably challenging, especially during a global health crisis.

There are inherent risks in mRNA therapeutics, requiring extensive testing, experimentation, and analysis. Concerns arise regarding potential immune responses or off-target effects, which could pose safety risks in the future and potentially impede market growth.

The mRNA therapeutics market faces competition from emerging technologies and established treatments that offer similar benefits without the potential safety concerns. These alternative therapies pose a threat to the growth of the mRNA therapeutics market.

Market Trends of the Global MRNA Therapeutics Market

mRNA Cancer Vaccines: The market for mRNA cancer vaccines is experiencing a notable and impactful trend. The development of cancer vaccines using mRNA technology presents a significant opportunity for advancements in oncology treatment and therapy.

Partnerships and Collaborations: Another prevailing trend in the market and related industries is the increasing focus on mRNA product development and the rise in expertise within the field. This is largely due to the growing number of collaborations and mergers among global pharmaceutical companies.

Orphan Diseases: The market has also witnessed the emergence of a significant trend involving the treatment of rare diseases. The therapeutics offered by this market have the potential to address medical needs that have previously gone untreated, particularly in the realm of orphan diseases. As a result, mRNA therapies are gaining increased attention from medical professionals and patients alike.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global mRNA Therapeutics Market by Type

Market Overview
Prophylactic Vaccines
Therapeutic Vaccines
Therapeutic Drugs

Global mRNA Therapeutics Market by Application

Market Overview
Rare Genetic Diseases
Oncology
Respiratory Diseases
Infectious Diseases
Others

Global mRNA Therapeutics Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

CureVac AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Moderna, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi SA (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioNTech SE (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dynavax Technologies Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Arcturus Therapeutics Holdings Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alnylam Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Modulus Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Catalent, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Translate Bio, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ionis Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vertex Pharmaceuticals Incorporated (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments